Mendus (OMX: IMMU)

Last close As at 25/12/2024

SEK8.46

−0.21 (−2.42%)

Market capitalisation

SEK427m

Mendus is a clinical-stage immunoncology (IO) company based in Sweden and the Netherlands. The company specialises in allogeneic dendritic cell biology and currently has two lead, cell-based, off-the-shelf therapies for haematological and solid tumours.

Latest Insights

View More

Healthcare | edison tv

Mendus – executive interview

Healthcare | Flash note

Mendus — Vididencel shines in ALISON trial (ovarian cancer)

Healthcare | Outlook

Mendus — Gearing up for the pivotal stages of development

Healthcare | Update

Mendus — Broad progress across the pipeline

Mendus_resized

Sector

Healthcare

Equity Analyst

Arron Aatkar

Analyst

Jyoti Prakash

Jyoti Prakash

Analyst, Healthcare

Key Management

  • Alex Karlsson-Parra

    CSO

  • Erik Manting

    CEO

  • Jeroen Rovers

    CMO

  • Leopold Bertea

    CTO

  • Lotta Ferm

    CFO

Research

Update

Healthcare

Mendus — Broad progress across the pipeline

edison tv

Healthcare

Mendus – executive interview

Flash note

Healthcare

Mendus — Collaboration unveils path forward for ilixadencel

edison tv

Healthcare

Executive interview with Erik Manting PhD, CEO of Mendus

Flash note

Healthcare

Mendus — Gross proceeds of c SEK69m to advance pipeline

Flash note

Healthcare

Mendus — Regulatory green light for CADENCE trial

Thematics

Subscribe to Edison

Get access to the very latest content matched to your personal investment style.

Sign up for free